News Provided By
Share This Article
Heart Blocks Treatment Devices Global Market Report 2024 – Market Size, Trends, And Global Forecast 2024-2033
The Business Research Company's Heart Blocks Treatment Devices Global Market Report 2024 – Market Size, Trends, And Global Forecast 2024-2033
You Can Now Pre Order Your Report To Get A Swift Deliver With All Your Needs”
— The Business Research Company
LANDON, GREATER LANDON, UK, July 15, 2024 / EINPresswire.com / -- The heart blocks treatment devices market has experienced robust growth in recent years, expanding from $3.11 billion in 2023 to $3.3 billion in 2024 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to growth in implantable cardioverter defibrillators (icds), evolution of cardiac resynchronization therapy (crt), miniaturization and leadless devices, clinical trials and evidence-based medicine, guidelines and recommendations, increasing incidence of cardiovascular diseases. Strong Future Growth Anticipated
The heart blocks treatment devices market is projected to continue its strong growth, reaching $4.13 billion in 2028 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to wireless connectivity and remote monitoring, expansion of wearable cardioverter defibrillators (wcds), personalized treatment algorithms, patient-centric design and comfort, increased adoption of mri-compatible device. Explore Comprehensive Insights Into The Global Heart Blocks Treatment Devices Market With A Detailed Sample Report:
Growth Driver Of The Heart Blocks Treatment Devices Market
The rising prevalence of cardiovascular disease is expected to propel the growth of the heart blocks treatment devices market going forward. Cardiovascular diseases affect the heart and blood vessels and include conditions such as coronary artery disease, heart failure, and stroke. The rapidly increasing incidence of cardiovascular disease is mostly driven by the aging population, changes in lifestyle and diet, and increasing rates of obesity and diabetes, where heart blocks treatment devices can be used to treat cardiovascular disorders by addressing abnormalities or defects in the structures and blocks of the heart. Make Your Report Purchase Here And Explore The Whole Industry's Data As Well:
Major Players And Market Trends
Key players in the heart blocks treatment devices market include MicroPort Scientific Corporation, GE HealthCare, Abbott Laboratories, Medtronic PLC, Koninklijke Philips N.V., Stryker Corporation, Boston Scientific Corporation, Nihon Kohden Corporation, Lepu Medical Technology (Beijing) Co., Zoll Medical Corporation, LivaNova PLC, Abiomed Inc., Cardiac Dimensions, EBR Systems Inc., Endotronix Inc., Calon Cardio, CVRx Inc., BioVentrix Inc., CorWave SA, Leviticus Cardio, BiVACOR, Biotronik SE and CO KG, CorMatrix Cardiovascular, Shree Pacetronix Ltd., Jarvik Heart Inc., Osypka Medical GmbH..
Major companies operating in the heart block treatment device market are focusing on technological advancements such as dual-chamber pacemakers to provide reliable services to customers. Dual-chamber pacemakers which refer to the technology of leadless pacing systems for treating abnormal or slow heart rhythms. Segments:
2) By Product: Transcutaneous Pacing (TCP), Pacemaker, Mediation, Follow-Up Electrophysiology Study
3) By End-user: Hospital Testing, Home treatment, Clinics, Other End-Users
Geographical Insights: North America Leading The Market
North America was the largest region in the heart blocks treatment devices market in 2023. Asia-Pacific is expected to be the fastest-growing region during the forecast period, driven by expanding healthcare facilities and increasing awareness of the benefits of heart blocks treatment devices. Heart Blocks Treatment Devices Market Definition
Heart blocks treatment devices are medical devices used to manage and correct disruptions in the electrical conduction system of the heart, specifically heart block. These devices help regulate the heart's rhythm and ensure proper coordination between the heart's chambers (atria and ventricles). • Market size data for the forecast period: Historical and Future
• Market analysis by region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa. • Market analysis by countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. Trends, opportunities, strategies and so much more. The Heart Blocks Treatment Devices Global Market Report 2024 by The Business Research Company is the most comprehensive report that provides insights on heart blocks treatment devices market size, heart blocks treatment devices market drivers and trends, heart blocks treatment devices market major players, heart blocks treatment devices competitors' revenues, heart blocks treatment devices market positioning, and heart blocks treatment devices market growth across geographies. The heart blocks treatment devices market report helps you gain in-depth insights into opportunities and strategies. Companies can leverage the data in the report and tap into segments with the highest growth potential. Browse Through More Similar Reports By The Business Research Company:
EV Battery Recycling Global Market Report 2024

Heart Blocks Treatment Devices Global Market 2024 To Reach $4.13 Billion By 2028 At Rate Of 5.7%

News Provided By
Share This Article
Ventricular Assist Device Market
A New Business Strategy report released by HTF MI with title Global Ventricular Assist Device Market Study Forecast till 2029. HTF MI integrates History, Trends, and Forecasts to identify the highest value opportunities, cope with the most critical business challenges and transform the businesses.”
— Criag Francis
PUNE, MAHARASHTRA, INDIA, June 22, 2023/ EINPresswire.com / -- According to HTF Market Intelligence, the Global Ventricular Assist Device Market to witness a CAGR of xx% during the forecast period (2023-2029). The Latest Released Ventricular Assist Device Market Research assesses the future growth potential of the Ventricular Assist Device market and provides information and useful statistics on market structure and size. This report aims to provide market intelligence and strategic insights to help decision-makers make sound investment decisions and identify potential gaps and growth opportunities. Additionally, the report identifies and analyses the changing dynamics and emerging trends along with the key drivers, challenges, opportunities and constraints in the Ventricular Assist Device market. The Ventricular Assist Device market size is estimated to increase by USD xx Million at a CAGR of % from 2023 to 2029. The Major Players Covered in this Report: Abbott Laboratories (United States), Berlin Heart GmbH (Germany), BiVACOR Inc. (United States), CardiacAssist Inc. (United States), Carmat SA (France), HeartWare International Inc. (United States), Jarvik Heart Inc. (United States), Leviticus Cardio Ltd. (Israel), Medtronic plc (Ireland), MicroMed Cardiovascular Inc. (United States), ReliantHeart Inc. (United States), St. Jude Medical Inc. (United States),
Get Quick Access to Sample Pages Now @ https://www.htfmarketintelligence.com/sample-report/global-ventricular-assist-device-market
Definition:
A ventricular assist device (VAD) is a mechanical pump that is implanted inside a patient's chest to help the heart pump blood. It is used in patients with severe heart failure who are awaiting heart transplant or as a long-term treatment option for those who are not eligible for heart transplant. Get Complete Scope of Work @ https://www.htfmarketintelligence.com/report/global-ventricular-assist-device-market
The titled segments and sub-section of the market are illuminated below:
In-depth analysis of Ventricular Assist Device market segments by Types: Left Ventricular Assist Devices (LVADs), Right Ventricular Assist Devices (RVADs), Biventricular Assist Devices (BiVADs)) by Distribution Channels (Direct, Distributor
Detailed analysis of Ventricular Assist Device market segments by Applications: Bridge-To-Transplant (BTT), Bridge-To-Recovery (BTR), Destination Therapy (DT)
Major Key Players of the Market: Abbott Laboratories (United States), Berlin Heart GmbH (Germany), BiVACOR Inc. (United States), CardiacAssist Inc. (United States), Carmat SA (France), HeartWare International Inc. (United States), Jarvik Heart Inc. (United States), Leviticus Cardio Ltd. (Israel), Medtronic plc (Ireland), MicroMed Cardiovascular Inc. (United States), ReliantHeart Inc. (United States), St. Jude Medical Inc. (United States)
Geographically, the detailed analysis of consumption, revenue, market share, and growth rate of the following regions:
• The Middle East and Africa (South Africa, Saudi Arabia, UAE, Israel, Egypt, etc.) • North America (United States, Mexico & Canada)
• South America (Brazil, Venezuela, Argentina, Ecuador, Peru, Colombia, etc.) • Europe (Turkey, Spain, Turkey, Netherlands Denmark, Belgium, Switzerland, Germany, Russia UK, Italy, France, etc.) • Asia-Pacific (Taiwan, Hong Kong, Singapore, Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia). Objectives of the Report:
• -To carefully analyze and forecast the size of the Ventricular Assist Device market by value and volume. • -To estimate the market shares of major segments of the Ventricular Assist Device market. • -To showcase the development of the Ventricular Assist Device market in different parts of the world. • -To analyze and study micro-markets in terms of their contributions to the Ventricular Assist Device market, their prospects, and individual growth trends. • -To offer precise and useful details about factors affecting the growth of the Ventricular Assist Device market. • -To provide a meticulous assessment of crucial business strategies used by leading companies operating in the Ventricular Assist Device market, which include research and development, collaborations, agreements, partnerships, acquisitions, mergers, new developments, and product launches. The market is segmented by Application (Bridge-To-Transplant (BTT), Bridge-To-Recovery (BTR), Destination Therapy (DT)) by Type (Left Ventricular Assist Devices (LVADs), Right Ventricular Assist Devices (RVADs), Biventricular Assist Devices (BiVADs)) by Distribution Channels (Direct, Distributor) by End-User (Hospitals, Cardiac Centers, Ambulatory Surgical Centers) by Mode of Operation (Pulsatile, Continuous Flow) and by Geography (North America, South America, Europe, Asia Pacific, MEA). Key takeaways from the Ventricular Assist Device market report:
– Detailed consideration of Ventricular Assist Device market-particular drivers, Trends, constraints, Restraints, Opportunities, and major micro markets. – Comprehensive valuation of all prospects and threats in the
– In-depth study of industry strategies for growth of the Ventricular Assist Device market-leading players. – Ventricular Assist Device market latest innovations and major procedures. – Favourable dip inside Vigorous high-tech and market latest trends remarkable the Market. – Conclusive study about the growth conspiracy of Ventricular Assist Device market for forthcoming years. Enquire for customization in Report @ https://www.htfmarketintelligence.com/enquiry-before-buy/global-ventricular-assist-device-market
Major highlights from Table of Contents:
Ventricular Assist Device Market Study Coverage:
• It includes major manufacturers, emerging player’s growth story, and major business segments of Ventricular Assist Device market, years considered, and research objectives. Additionally, segmentation on the basis of the type of product, application, and technology. • Ventricular Assist Device Market Executive Summary: It gives a summary of overall studies, growth rate, available market, competitive landscape, market drivers, trends, and issues, and macroscopic indicators. • Ventricular Assist Device Market Production by Region Ventricular Assist Device Market Profile of Manufacturers-players are studied on the basis of SWOT, their products, production, value, financials, and other vital factors. • Key Points Covered in Ventricular Assist Device Market Report:
• Ventricular Assist Device Overview, Definition and Classification Market drivers and barriers
• Ventricular Assist Device Market Competition by Manufacturers
• Ventricular Assist Device Capacity, Production, Revenue (Value) by Region (2023-2029)
• Ventricular Assist Device Supply (Production), Consumption, Export, Import by Region (2023-2029)
• Ventricular Assist Device Production, Revenue (Value), Price Trend by Type {}
• Ventricular Assist Device Market Analysis by Application {}
• Ventricular Assist Device Manufacturers Profiles/Analysis Ventricular Assist Device Manufacturing Cost Analysis, Industrial/Supply Chain Analysis, Sourcing Strategy and Downstream Buyers, Marketing
• Strategy by Key Manufacturers/Players, Connected Distributors/Traders Standardization, Regulatory and collaborative initiatives, Industry road map and value chain Market Effect Factors Analysis. Major questions answered:
• What are the influencing factors driving the demand for Ventricular Assist Devices near future? • What is the impact analysis of various factors in the Global Ventricular Assist Device market growth? • What are the recent trends in the regional market and how successful they are? • How feasible is Ventricular Assist Device market for long-term investment? Thanks for reading this article; you can also get individual chapter-wise sections or region-wise report versions like North America, MINT, BRICS, G7, Western / Eastern Europe, or Southeast Asia. Also, we can serve you with customized research services as HTF MI holds a database repository that includes public organizations and Millions of Privately held companies with expertise across various Industry domains. Criag Francis

Ventricular Assist Device Market Eyeing Bigger Moves: Abbott, BiVACOR, Jarvik Heart

Breakthrough in Device Therapy for Patients with Late-Stage Heart Disease
Editors note: News of this development appeared in PR Newswire. Severe heart failure is the most life-threatening medical condition in all age groups across the globe. Implantable heart pumps, known as Ventricular Assist Devices (or VADs), have proven to sustainably increase long term survival. However, due to the need for tethering to an external power source using a cable exiting the body through the abdomen, these devices have not yet been fully accepted as mainstream therapy. Now, for the first time globally, a compact, fully implantable  VAD (FiVAD)  has been successfully implemented by combining the Calon Cardio MiniVAD™ with the versatile, fully implantable wireless energy recharging system of  Leviticus Cardio . Completion of a 60-day in-vivo pre-clinical study of this FiVAD has successfully validated the integration of these two innovative technologies. This new disruptive technology, FiVAD, will allow a patient a full day without a cable or connection to any external equipment whatsoever. The recharging process itself only requires a light belt around the patient’s chest during the night. The successful elimination of the electric power cable is a major step forward leading to a near-normal quality of life for these severely ill patients. It will convince physicians around the world that VAD therapy has reached the point of routine use and will lead to widespread application of this life saving therapy. The trial was conducted at the internationally recognized Centre of Excellence at the Catholic University of Leuven, in Belgium. The success of this ground-breaking study marks a further step in the integration of the two companies who are committed to taking this life changing innovation in partnership to patients across the globe. Stuart McConchie, CEO of Calon Cardio-Technology Ltd:
The combination of our MiniVAD, designed to optimize blood handling, and the Leviticus wireless technology provides a safe and usable truly wireless VAD system, representing major progress in blood pump technology. Together this FiVAD will significantly improve the lives of vast numbers of late-stage heart failure patients. Michael Zilbershlag, CEO of Leviticus Cardio Ltd:
Our study has demonstrated that the combination of the very effective Calon MiniVAD™ and the Leviticus FiVAD offers for the first time a fully functioning heart pump without the need to be recharged for more than 10 hours allowing freedom from any external equipment for a whole working day. Marc Clement, Chairman of Calon Cardio-Technology Ltd:
I am sure I speak for both companies when I say how delighted we are with the outcome of the integration of our respective ground-breaking technologies. We are committed to a long-term relationship that will improve the quality of life of thousands of patients across the world. The successful 60-days preclinical milestone of the MiniVAD and FiVAD platform poses an encouraging accomplishment in further integration of these two innovative technologies,
 
states Professor Ivan Netuka, Cardiac Surgeon, a Chairman in the Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic. Professor Stephen Westaby, renowned heart surgeon (now retired) and a founder of Calon Cardio impresses that
The critical importance of the integration of the Calon Cardio and Leviticus Cardio technologies is the elimination of driveline infection. Infection destroys quality of life, promotes thrombosis and stroke, and too often results in substantial early mortality. The integrated FiVAD is a system that has the potential to supersede cardiac transplant as the preferred intervention in advanced heart failure, without needing someone else to die first. A system like this will give patients the freedom to do what they like for more than a whole working day without any external cable connections. When in clinical practice, this is more than we as physicians could have ever dreamed for VAD patient quality of life,
 
adds Professor Stephan Schueler, Head of Department of Cardiothoracic Surgery at The Newcastle Upon Tyne Hospitals NHS Foundation Trust, United Kingdom.

Breakthrough in Device Therapy for Patients with Late-Stage Heart Disease

USA - English
News provided by
Share this article
Share this article
SWANSEA, Wales and TEL AVIV, Israel, Jan. 10, 2022 /PRNewswire/ -- Severe heart failure is the most life-threatening medical condition in all age groups across the globe. Implantable heart pumps, known as Ventricular Assist Devices (or VADs), have proven to sustainably increase long term survival. However, due to the need for tethering to an external power source using a cable exiting the body through the abdomen, these devices have not yet been fully accepted as mainstream therapy. Now, for the first time globally, a compact, fully implantable VAD (FiVAD) has been successfully implemented by combining the Calon Cardio MiniVAD™ with the versatile, fully implantable wireless energy recharging system of Leviticus Cardio. Completion of a 60-day in-vivo pre-clinical study of this FiVAD has successfully validated the integration of these two innovative technologies. This new disruptive technology, FiVAD, will allow a patient a full day without a cable or connection to any external equipment whatsoever. The recharging process itself only requires a light belt around the patient's chest during the night. The successful elimination of the electric power cable is a major step forward leading to a near-normal quality of life for these severely ill patients. It will convince physicians around the world that VAD therapy has reached the point of routine use and will lead to widespread application of this life saving therapy. The trial was conducted at the internationally recognised Centre of Excellence at the Catholic University of Leuven, in Belgium. The success of this ground-breaking study marks a further step in the integration of the two companies who are committed to taking this life changing innovation in partnership to patients across the globe. Stuart McConchie, CEO of Calon Cardio-Technology Ltd: "The combination of our MiniVAD, designed to optimize blood handling, and the Leviticus wireless technology provides a safe and usable truly wireless VAD system, representing major progress in blood pump technology. Together this FiVAD will significantly improve the lives of vast numbers of late-stage heart failure patients." Michael Zilbershlag, CEO of Leviticus Cardio Ltd: "Our study has demonstrated that the combination of the very effective Calon MiniVAD™ and the Leviticus FiVAD offers for the first time a fully functioning heart pump without the need to be recharged for more than 10 hours allowing freedom from any external equipment for a whole working day." Marc Clement, Chairman of Calon Cardio-Technology Ltd: "I am sure I speak for both companies when I say how delighted we are with the outcome of the integration of our respective ground-breaking technologies. We are committed to a long-term relationship that will improve the quality of life of thousands of patients across the world." "The successful 60-days preclinical milestone of the MiniVAD and FiVAD platform poses an encouraging accomplishment in further integration of these two innovative technologies," states Professor Ivan Netuka, Cardiac Surgeon, a Chairman in the Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic. Professor Stephen Westaby, renowned heart surgeon (now retired) and a founder of Calon Cardio impresses that "The critical importance of the integration of the Calon Cardio and Leviticus Cardio technologies is the elimination of driveline infection. Infection destroys quality of life, promotes thrombosis and stroke, and too often results in substantial early mortality. The integrated FiVAD is a system that has the potential to supersede cardiac transplant as the preferred intervention in advanced heart failure, without needing someone else to die first." "A system like this will give patients the freedom to do what they like for more than a whole working day without any external cable connections. When in clinical practice, this is more than we as physicians could have ever dreamed for VAD patient quality of life," adds Professor Stephan Schueler, Head of Department of Cardiothoracic Surgery at The Newcastle Upon Tyne Hospitals NHS Foundation Trust, United Kingdom. About Calon Cardio-Technology Ltd
Calon Cardio  was founded by Professor Stephen Westaby, Cardiac Surgeon, and Professor Marc Clement, Physicist, to optimise the heart failure therapy provided by early ventricular assist devices. The focus of this work was on reducing damage caused by shear forces during the passage of blood components through a pump. By achieving this objective, the clinical value of VAD therapy is increased, and at the same time, the overall cost is reduced. The Company has been supported financially by the Development Bank of Wales, by UK Government Grants, Longbow Capital, and more recently by the UK Future Fund program. Calon has drawn significant support from UK, US, and EU equity investors. About Leviticus-Cardio Ltd.
Leviticus Cardio  is a medical device company dedicated to improving the clinical outcome for patients with an implanted left ventricular assist device (LVAD) for the treatment of impaired cardiac function. The Leviticus FiVAD received several innovation awards, was implanted in humans in 2018/9 and received Breakthrough Device Designation from the FDA in 2019. The Company has received funding from The Trendlines Group (SGX:42T) (OTCQX: TRNLY ), a consortium of acclaimed cardiovascular physicians, private investors, and Israel's Innovation Authority. Contacts:

07:00 ET
Breakthrough in Device Therapy for Patients with Late-Stage Heart Disease

|ABIOMED Inc, Berlin Heart GmbH, CardiacAssist Inc
Pune, Maharashtra, India, September 14 2020 (Wiredrelease) MarketResearch.Biz –:The recent report posted via MarketResearch.Biz on Circulatory Support Devices market offers critical market insights in conjunction with targeted segmentation evaluation . The report examines key using elements which might be anticipated to drive the increase of the market. Global Circulatory Support Devices Market Research Report offers crucial data on numerous market situations, for example, ability improvement elements, elements controlling the advancement, market possibilities, and risks to the global market. Also, the report widely facilities round competitive evaluation of Circulatory Support Devices Market. The competitive evaluation section includes key producers, recent players, providers, market strategies, ability chances, operation panorama, and evaluation of the traits of the Circulatory Support Devices market. The market consequences are targeted by round the present market scenario. To gauge and expect the competitive scenario on this market. This report will likewise assist all of the producers and speculators to have an advanced comprehension of the investments to recognize wherein the market is heading. For Better Understanding, Request A Free Pdf Sample Copy Of Circulatory Support Devices Market Here@ https://marketresearch.biz/report/circulatory-support-devices-market/request-sample
(***Our FREE SAMPLE COPY of the report offers a quick advent to the studies report outlook, TOC, a listing of tables and figures, an outlook to key players of the market, and comprising key regions.) Leading players of Circulatory Support Devices including:
ABIOMED Inc, Berlin Heart GmbH, CardiacAssist Inc, Corwave SAS, Evaheart Inc, Jarvik Heart Inc, Leviticus Cardio Ltd, Medtronic plc., ReliantHeart Inc, Jude Medical Inc, CHF Solutions, Inc
Segmentation by product: Total Artificial Heart, Ventricular Assist Device, Extracorporeal Membrane Oxygenation. Segmentation by end user: Hospitals, Ambulatory Centers
Download Now And Browse Complete Information On The COVID 19 Impact Analysis On Circulatory Support Devices Market: https://marketresearch.biz/report/circulatory-support-devices-market/covid-19-impact
Circulatory Support Devices Report Covers Following Questions:
1. What will the market increase rate, increase momentum of Circulatory Support Devices market
2. What is the envisioned size of the rising Circulatory Support Devices market in 2029? 3. Which section is anticipated to account for the most important Circulatory Support Devices market percentage by 2029? 4. What are sales, revenue, and value evaluation by areas of Circulatory Support Devices market? 5. What are the market risk, market possibility and market review of the Circulatory Support Devices market? 6. Who are the distributors, dealers, and buyers of Circulatory Support Devices market? Moreover, the report in brief research the overall performance of each historic statistics in conjunction with the current traits. It consists of an entire evaluation of various attributes inclusive of production base, type, and size. This report evaluates the market segmentation in conjunction with the competitive panorama worldwide in addition to the local level. The report additionally discusses approximately the growing want for Circulatory Support Devices market. Reasons for Buying this Report
The worldwide Circulatory Support Devices market report offers a forward-searching attitude on Driving and restraining elements of the market increase. Ten-year forecast assessed on the premise of how the market is expected to grow
Future evaluation is moreover supplied on how the market is predicted to grow
Past market dynamics of the past years
Helps in know-how the important thing product segments and their future estimations
Focused evaluation of converting competitive dynamics to recognize the procedures utilized by the numerous key players withinside the market
Any Query? Feel Free To Enquire Here: https://marketresearch.biz/report/circulatory-support-devices-market/#inquiry
Report on Global Circulatory Support Devices Market 2020 contains of 10 Sections in Table as follows: –
Industry Overview of Circulatory Support Devices: Includes numerous definitions, specs in conjunction with its features, and applicability. Circulatory Support Devices Manufacturing Cost & Price Structure Analysis: Raw Material required and their suppliers, price shape evaluation on the subject of production, structural evaluation of promoting price, break-even factor evaluation, and procedure evaluation. Production Description: Capacity and Commercial Production Date of Circulatory Support Devices Major Manufacturers in 2020, Manufacturing Plants Distribution, R&D Status, and Technology Source and Raw Materials Sources Analysis. Global Circulatory Support Devices Overall Market Overview: Overall Market Analysis starting from Production to Revenue
Global Circulatory Support Devices segmentation:
By Type: – Sales and Factors impacting the increase in sales. By Application: – Consumer evaluation in conjunction with the end-user evaluation. Analysis of Major Manufacturers of Circulatory Support Devices across the world: Examination of every Company profiles, picture of the object and details, sales, preceding costs, income, Gross Margin Analysis, Business Region Distribution Analysis
The trend of Circulatory Support Devices Market: Circulatory Support Devices Market Trend Analysis, Market Size (Volume and Value) Forecast, Regional Market Trend, Market Trend via way of means of Product Type and Applications. Browse The Complete TOC of the Report: https://marketresearch.biz/report/circulatory-support-devices-market/#toc
The Circulatory Support Devices market report reads pin-direct evaluation for converting extreme dynamics in regards to converting factors that drive or limits market improvement. The report is comprehensively visualized to forecast the market factor of view and possibilities wherein it has an extension to expand in the future. Basically, the report segregates the potential of the market withinside the current and the upcoming opportunities from numerous edges in detail. About Us:
MarketResearch.Biz is a specialized market research, analytics, and solutions company, offering strategic and tactical support to clients for making well-informed business decisions. We are a team of dedicated and impassioned individuals, who believe strongly in giving our very best to what we do and we never back down from any challenge. The company offers services such as data mining, information management, and revenue enhancement solutions and suggestions. We cater to industries, individuals, and organizations across the globe, and deliver our offerings in the shortest possible turnaround time. Contact Us:

Circulatory Support Devices Market Challenges, Future Perspectives and Projected Growth Analysis|ABIOMED Inc, Berlin Heart GmbH, CardiacAssist Inc

Leviticus Cardio

Abbott

The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.

Digital Health

Grant

Leviticus Cardio develops medical technology within the healthcare sector, focusing on solutions for patients with chronic heart failure (CHF). The company offers a hybrid solution that integrates its Coplanar Energy Transfer (CET) technology with existing Ventricular Assist Devices (VADs), resulting in a system that is wirelessly charged and intended to assist CHF patients. Leviticus Cardio's products are targeted at the medical devices industry, with an emphasis on solutions for heart disease management. It was founded in 2008 and is based in Petah Tikva, Israel.

Date	Round	Amount	Investors	Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.	Revenue	Sources
1/9/2019	Grant		BIRD Foundation	$XXM	0 FY undefined	1
4/13/2015	Unattributed - II	$XXM	Subscribe to see more	$XXM	0 FY undefined	10
10/13/2013	Unattributed	$XXM	Subscribe to see more	$XXM	0 FY undefined	10
	Other Investors		Subscribe to see more	$XXM	0 FY undefined	0

Date	1/9/2019	4/13/2015	10/13/2013
Round	Grant	Unattributed - II	Unattributed	Other Investors
Amount		$XXM	$XXM
Investors	BIRD Foundation	Subscribe to see more	Subscribe to see more	Subscribe to see more
Valuation	$XXM	$XXM	$XXM	$XXM
Revenue	0 FY undefined	0 FY undefined	0 FY undefined	0 FY undefined
Sources	1	10	10	0

First funding	Last Funding	Investor	Rounds	Board Seats	Type	Location
1/9/2019	1/9/2019	BIRD Foundation	1 Grant		Non-Profit Foundation	Israel
		The Trendlines Group	Subscribe to see more		Venture Capital	Israel

First funding	1/9/2019
Last Funding	1/9/2019
Investor	BIRD Foundation	The Trendlines Group
Rounds	1 Grant	Subscribe to see more
Board Seats
Type	Non-Profit Foundation	Venture Capital
Location	Israel	Israel

How VCs Use CB Insights

Professional Services

Platform Overview

Leviticus Cardio

Total Raised

Investors Count

Funding, Valuation & Revenue

Leviticus Cardio Investors